- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04094649
Acute Study of Effect of Ultrasound Vagus Nerve Stimulation on Glycemia
This is a Single-site, Double-blind, Randomized, Prospective, Sham-controlled, Crossover Early Feasibility Study to Determine Whether Ultrasound Vagus Nerve Stimulation (uVNS) Inhibits Postprandial Hyperglycemia in Humans
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The DECIMA device comprises an array of two focused ultra-sound applicators arranged with overlapping foci to deliver acoustic energy to a known focal depth within tissue. The focused ultrasound applicators are each comprised of an ultra-sound-emitting piezoelectric element coupled to a focusing lens. The array of the DECIMA device is coupled with an ultra-sound imaging system to locate the cervical vagus nerve, and a control system to deliver short bursts of ultrasound energy that are controlled by the operator in time and intensity.
The imaging system and the array of applicators are calibrated together, so the power is focused at a known location relative to the imaging system screen. Each focused applicator's lens is joined to an ultrasound coupling cylinder filled with water. Each coupling cylinder is lined with thin plastic film at the skin. The ultrasound output power of the applicators is monitored by each applicator's control unit which includes a display of the ultrasound intensity.
To perform ultrasound stimulation, ultrasound gel is placed on the skin over the nerve area in the neck. Then the coupling cylinders and imaging transducer are placed against the gel, then the DECIMA position is fixed in place by a support arm.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- Cognitive Clinical Trials, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent prior to any of the screening procedures
- Willingness to comply with all study procedures and available for the duration of the study
- Male or female age between 21 and 60 years old, inclusive
- Diabetes Mellitus Type 2 for at least 1 year
Exclusion Criteria:
- HbA1c greater than 10.5%
- Medical treatment regimen with insulin
- Medical treatment with antiinflammatory drugs such as Disease-Modifying Antirheumatic Drugs (DMARDs), i.e. Methotrexate and Cytokine-inhibitors, e.g. Adalimumab, and Etanercept.
- Clinically significant neuropathy in the opinion of the investigator or as documented in the subject's medical history
- Abundant fat tissue in neck, as evidenced by a neck circumference of more than 20''
- Clinically significant surgical procedure(s) or skin lesion(s) in neck that would affect subject safety or placement of device
- Prior vagotomy
- History of clinically significant vasovagal syncope or presyncope
- Use of electrically active implanted medical device
- History of heat stroke or any heat intolerance that is deemed clinically significant in the opinion of the investigator
- History of renal dysfunction or a glomerulonephropathy defined as either nephritic or nephrotic syndrome, including estimated glomerular filtration rate of <30 mL/min
- Clinically significant cardiovascular condition or problem that in the opinion of the investigator would interfere with the study data or affect patient safety (e.g. uncontrolled hypertension, congestive heart failure, or documented evidence of prior coronary artery disease).
- Pregnancy or plans to become pregnant while participating in the study, as determined by urine pregnancy test conducted at the screening visit for women of childbearing potential. A woman of childbearing potential is defined as a premenopausal female capable of becoming pregnant. This includes women on oral, injectable, or mechanical contraception; women who are single; women whose husbands have been vasectomized or whose husbands have received or are utilizing mechanical contraceptive devices.
- Uncontrolled asthma or obstructive lung disease.
- History of sepsis
- Significant cardiac rhythm disturbances in the opinion of the investigator based on an ECG.
- GI surgery that could have lacerated any branch of the vagus nerve, i.e. cholecystectomy, gastrectomy, pancreatic surgery, etc.
- Other conditions that could impair the patient's ability to participate in the study according to the investigator's opinion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Sham vs Active Stimulation Positions
Adults with Diabetes Mellitus Type 2 (DMT2) will be recruited and randomized to active uVNS or sham across two sessions according to a 2x2 crossover design.
Sham uVNS will be delivered with the same stimulation parameters as active uVNS, but will be targeted to the left sternocleidomastoid muscle ~2 cm away from the vagus nerve.
|
This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.
|
Active Comparator: Active uVNS
Active stimulations will be targeted with the ultrasound beam of the DECIMA device .Active uVNS will be delivered to the left cervical vagus nerve following the OGTT through the 60-min time point.
|
This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in blood glucose Area Under the Curve (AUC, mg/dL ● hours) from baseline to 3 hours after an Oral Glucose Tolerance Test (OGTT) with Ultrasonic Vagus Nervous Stimulation (uVNS).hyperglycemia
Time Frame: Change from baseline in the 3-hour mean glucose AUC following an OGTT
|
The DECIMA device comprises an array of two focused ultra-sound applicators arranged with overlapping foci to deliver acoustic energy to a known focal depth within tissue.
|
Change from baseline in the 3-hour mean glucose AUC following an OGTT
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in whole blood lipospolysaccharide-induced TNF-Alpha (pg/mL) production from base line to 4 hours post stimulation.
Time Frame: Change in mean Whole Blood Lipopolysaccharide-Induced TNF production from baseline to four (4) hours post-stimulation
|
Inhibits postprandial hyperglycemia in patients with Diabetes Mellitus Type 2 via a temperature-medicated mechanism.
|
Change in mean Whole Blood Lipopolysaccharide-Induced TNF production from baseline to four (4) hours post-stimulation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Albert Tejada, MD, PI, Synexus
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AT-C-19-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on Ultrasound Vagus Nerve Stimulation (DECIMA)
-
Peking University People's HospitalEnrolling by invitationChemotherapy-induced Peripheral Neuropathy | CIPNChina
-
Northwell HealthCompletedStroke | Hemiparesis | Cerebrovascular Accident (CVA)United States
-
University Hospital, GhentResearch Foundation FlandersCompletedEpilepsyBelgium, United States
-
Baylor Research InstituteUniversity of Texas Southwestern Medical Center; Wings for Life; The University... and other collaboratorsRecruitingSpinal Cord Injuries | Upper Extremity ParesisUnited States
-
University Medical Centre LjubljanaCompletedIschemic Heart Disease | Arterial HypertensionSlovenia
-
Baylor Research InstituteNational Institute of Neurological Disorders and Stroke (NINDS); University... and other collaboratorsRecruitingStroke | Ischemic Stroke | Hemorrhagic Stroke | Upper Extremity Paresis | Chronic StrokeUnited States
-
Xidian UniversityUnknown
-
Xuzhou Central HospitalThe Affiliated Hospital of Xuzhou Medical University; The First People's Hospital...Not yet recruitingPostoperative Delirium | Postoperative Cognitive Dysfunction | Chronic Post Operative PainChina
-
University Hospital, GrenobleRecruiting
-
Sahlgrenska University Hospital, SwedenRecruitingBorderline Personality DisorderSweden